Cancer treatment in Japan. Immunotherapy. The vaccine against cancer.

Cancer treatment in Japan. Immunotherapy. The vaccine against cancer.

Japan has been and remains one of the leading countries in many areas. Medicine is no exception.

Every year, clinical trials are conducted in the country and new cancer treatment methods are launched. But besides treatment, there are two other important areas in which Japan also has extensive experience. This is the prevention of oncological processes in the body, as well as the maximum recovery after treatment and the prevention of relapses.

The main focus of the research was human immunity and working with it.

Let's Talk About the "mechanism" of the immune system

The immune system, which protects the body from diseases, consists of two mechanisms: innate immunity and acquired immunity.

Innate immunity is a system that is embedded in the body. She constantly monitors the condition of the body and quickly launches an attack against the penetration of foreign substances. This is, so to speak, the "initial line of defense" against the disease.

Acquired immunity reacts to foreign substances that break through the "first line of defense."
Acquired immunity is a system that only advanced life forms, such as humans, possess.

It has a powerful destructive power and attacks "strong enemies" such as cancer cells. It is thanks to this system that we have antibodies against certain diseases.

The warriors of the "innate immune system" that take the lead in attacking cancer cells that have invaded the body are granulocytes, NK cells, dendritic cells, and macrophages.

Of these, dendritic cells play a particularly important role.

They are called the "commanders-in-chief of the immune system", they detect enemy information such as "antigens" and pass it on to the "acquired immunity" team waiting in the lymph nodes.
Warriors of acquired immunity include:

•  T cells (CTL = killer, T cells), which have a powerful ability to kill,
•  B cells, which are mainly used against small foreign enemies. They launch a powerful attack on the target of the enemy attack, that is, on the antigen that the dendritic cells informed them about.

The Hasumi vaccine

This knowledge has enabled scientists to think about a vaccine against cancer. This is how one of the first cancer vaccines, the Hasumi vaccine, appeared.

The Hasumi vaccine treatment method was developed by Kiichiro Hasumi, MD, in 1948, and has been used for more than half a century to treat various types of tumors by more than forty thousand cancer patients worldwide. The most typical indication for the use of the Hasumi vaccine is the prevention of tumor recurrence after or in combination with current treatment, including alternative methods, without causing serious side effects.

The effect of vaccines is largely determined by the Marignase adjuvant, which has the ability to improve cellular immunity, and at the same time the vaccine has anti-allergic and anti-inflammatory effects.

"Adjuvants" are substances that activate immune activity by acting on dendritic cells. This is such an important substance that the effectiveness of any immunotherapy depends to no small extent on the effect of the adjuvant.

The adjuvant developed by Shukokai, which manufactures the Hasumi vaccine, has a "reliable effect" and is made from components that are naturally present in the body, so it is easily absorbed by the body and "has almost no side effects."

This is typical for adjuvant therapy. Adjuvant therapy uses these high-quality adjuvants to "improve health" and ultimately "anti-aging" by "preventing cancer" and keeping the body's immune system young at all times.

The goal is to realize "anti-aging" by keeping the body's immune system young, including "cancer prevention."

In general, Hasumi vaccine therapy can give better results when the disease is in a stable stage than in an amphibious one.

Prevention of tumor recurrence with the Hasumi vaccine

Hasumi vaccine therapy is recommended to maintain the positive results of standard treatments such as surgery, chemotherapy, and radiation therapy in order to prevent recurrence and/or metastasis.

The Hasumi vaccine is recommended to be used in parallel with the indicated treatment methods, as an addition to the treatment regimens developed by the patient's attending physician.

The most typical indication for the use of the Hasumi vaccine is the prevention of tumor recurrence after or in combination with current treatment and for regenerative purposes.

The effectiveness of the Hasumi vaccine was demonstrated by a 10-30% increase in five-year survival in patients with various types of tumors, compared with 1-6% in the group of patients receiving traditional treatment.

In cases of advanced cancer, the five-year survival rate is 2-3%. However, even in such cases, the Hasumi vaccine shows improved quality (increased activity, increased body weight, and decreased fatigue). These positive effects can be achieved with a vaccine characterized by fewer concomitant adverse events compared to standard therapy.

The Hasumi vaccine should begin to strengthen the patient's own immune system after an average of 3 months of continuous use. About 60% of patients subjectively noted pain relief, improved appetite, and weight gain.

Three months after using the vaccines, the patients were examined using cancer markers, and about 26% showed improvement. The results of hematological studies also indicate an improvement in anemia, an increase in total protein levels, and an improvement in the rate of erythrocyte sedimentation, which was observed in about 70% of patients.

The Hasumi vaccine is a very versatile vaccine that can be effective for patients from stage 0 to stage IV. It should be used depending on the situation, after consulting with a doctor.

The Hasumi vaccine comes in several types, differing in the type of "antigen":

They are mainly divided into two types: conventional and autologous vaccines. The difference between the two lies in the type of "antigen" contained in the vaccine.

The antigens for conventional vaccines are produced from "cancer cell membranes." Example: antigens are produced from cell membranes extracted from cultured cancer cells of various types, such as "stomach cancer", "colorectal cancer", "breast cancer".

Vaccines are made for each type of cancer separately, so people with stomach cancer are prescribed a "stomach cancer vaccine", and people with breast cancer are prescribed a "breast cancer vaccine", etc.

An autologous vaccine is made from antigens present in the patient's urine. In most cases, if cancer cells remain in the body, the "cancer cell membrane protein molecules" that circulate in the body leak out into the urine. These tiny amounts of "cancer cell membrane protein molecules" are collected, fragmented antigens are isolated from them and a vaccine called an "Autologous vaccine" is made from them.

The choice between a "Conventional vaccine" and an "Autologous vaccine" depends on whether cancer cells are present in the patient's body. If the tumor has already been surgically removed and there is no long-term recurrence, that is, there are no cancer cells in the body, a conventional vaccine is used.

Autologous vaccines are used by patients who have (or may have) cancer cells in their bodies, for example, those who have not had surgery, who have recently had surgery, who have had surgery but have high tumor markers, or for those who have had a relapse.